The FINANCIAL -- EnterNext, the Euronext subsidiary designed to promote and grow the market for mid and small capitalisations, welcomes on June 30 Mithra Pharmaceuticals SA, a Belgian company focused on women’s health, on the regulated market of Euronext Brussels.
Mithra is a pharmaceutical company focused on the development, manufacturing and commercialisation of proprietary, innovative and differentiated drugs and complex generic products dedicated to female healthcare. Mithra is specialised in four different domains of Women’s Health: contraception and fertility, menopause and osteoporosis, gynecological infections and cancers, according to Euronext.
Mithra (ticker code: MITRA)issued 6.023.809 new shares at a reference price of EUR 12 per share, giving the company an initial market capitalisation of EUR 366.5 million. The transaction raised a total of EUR 72.3 million.
François Fornieri, CEO of Mithra Pharmaceuticals, said : “It is a great honour for Mithra to inaugurate the new Euronext offices with this first IPO. For us, this is the result of four months of intensive work to reach a market capitalization of more than 366 million euros for Mithra. We have managed to raise 72,3 million euros through this IPO, an amount which will enable us to both finance research projects and to grow as a company.”
Vincent Van Dessel, CEO of Euronext Brussels, declared: “We are delighted to host such a successful company on our European market. The listing of Mithra on Europe’s leading stock exchange demonstrates the attractiveness of public equity as a source of financing the real economy and helping companies achieve their funding needs.”
Alain Baetens, Head of Listings of Euronext Brussels,added: “The IPO of Mithra was warmly welcomed by institutional and retail investors, which stresses the quality of Euronext Brussels as a major financing centre for innovative and ambitious entrepreneurs. It is the largest pharmaceutical IPO in the euro zone this year. With the support of the Enternext solutions for mid & small caps, Mithra will benefit from the access to a wide range of services that will help to raise its visibility and liquidity as a listed company.”
To celebrate the listing, François Fornieri, CEO of Mithra Pharmaceuticals, rang the bell in Brussels to open trading on Euronext’s European markets.